Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

NICE Approves Maintenance Rucaparib for Relapsed Ovarian Cancer

October 11th 2019

The UK’s National Institute for Health and Care Excellence has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy.

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

October 10th 2019

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

October 9th 2019

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

PARP Inhibitors Continue to Flourish in Advanced Ovarian Cancer

October 7th 2019

Reagan M. Street, MD, MMS, discusses the shift toward targeted treatment in advanced ovarian cancer partly brought on by PARP inhibitors and the importance of hierarchical genomic testing.

Trametinib Emerges as New Standard Option for Recurrent, Low-Grade Ovarian Cancer

October 4th 2019

Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.

Nivolumab/Ipilimumab Combo Delivers Durable Clinical Activity in Cervical Cancer

October 1st 2019

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

Nivolumab Shows Marked Activity in Recurrent Metastatic Gynecologic Cancers

September 26th 2019

Nivolumab monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer.

Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena

September 25th 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.

FDA Approves Lenvatinib/Pembrolizumab Combo for Advanced Endometrial Cancer

September 17th 2019

The FDA has granted an accelerated approval to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, and who have disease progression following prior systemic therapy but are ineligible for curative surgery or radiation.

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

September 10th 2019

Ghanshyam Yadav, MD, discusses research surrounding the combination of the PARP inhibitor olaparib and the pan-HER TKI neratinib, which proved to be highly synergistic and had significant activity in preclinical models of HER2-positive uterine serous carcinoma.

The New Ovarian Cancer Landscape: Many Questions, Much Hope

September 3rd 2019

In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.

Projecting the Impact of Immunotherapy in Advanced Ovarian Cancer

August 30th 2019

Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.

Navigating Among Maintenance Options in Advanced Ovarian Cancer

August 30th 2019

Camille C. Gunderson, MD, discusses the various maintenance options available in advanced ovarian cancer, as well as what factors should be considered for selecting each approach.

PARP Inhibition: A Necessity of Treatment in Recurrent Ovarian Cancer

August 29th 2019

Debra Richardson, MD, FACOG, FACS, discusses the current indications for PARP inhibitors in the recurrent setting and ongoing work being done to broaden their utility in the field.

Neoadjuvant Chemo Safer Alternative for Certain Patients With Ovarian Cancer

August 29th 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

Strategies Emerging for PARP Inhibitor Resistance in Ovarian Cancer

August 28th 2019

Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.

Hope Is Not Lost on Hunt for Effective Ovarian Cancer Screening Test

August 28th 2019

Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.

Prolonging PFS With PARP Inhibitors in Platinum-Sensitive Ovarian Cancer

August 22nd 2019

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Frontline Data for Newly Diagnosed Ovarian Cancer Leave Much to Be Discerned

August 22nd 2019

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

August 22nd 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.